Beyond the Lab Rat: The Bipartisan Push to Replace Animal Testing in US Drug Development

In the fall of 1937, a Tennessee drug manufacturer called the S.E. Massengill Company sold a liquid form of the antibiotic sulfanilamide, an antibiotic used to treat streptococcal infections. The drug was dissolved in diethylene glycol (DEG), a toxic chemical that today is used in brake fluid, lubricants, and antifreeze. Before producing the drug, the company’s chief chemist failed to consult existing studies that had identified DEG’s toxicity; even after producing the drug, the company never conducted any safety studies on the formula. As a result of this negligence, at least 100 people died of poisoning from the drug. This crisis in public health pushed Congress to establish safety regulations such as the 1938 Food, Drug, and Cosmetic Act, and ultimately led to the creation of the modern Food and Drug Administration (FDA). 

The law established standards for proving that new drugs were safe before reaching the public, and drug developers have since relied largely on animal testing to provide that proof. Today, organ chips, computer models, and artificial intelligence offer new ways to predict how drugs affect the human body. Lawmakers across the political spectrum question whether these new methods could substitute the country’s reliance on animal testing––a rare point of bipartisan agreement in health policy. Rather than whether the United States should move away from animal testing, the central debate around this topic has become how quickly this shift should occur and whether the scientific methods intended to replace it are equally sufficient for ensuring the public’s health and safety.

President Franklin D. Roosevelt signed the Federal Food, Drug, and Cosmetic Act on June 25, 1938. For the first time in the country’s history, the law required manufacturers to prove to the FDA that new drugs were safe before selling them. The 1938 law did not explicitly inhibit or implore companies to use animal testing to do so. However, because no alternatives existed at the time, animal studies became the standard way for the pharmaceutical industry to demonstrate drug safety. The FDA’s own account of the Massengill crisis notes that a few tests on animals would have revealed the drug’s lethal properties. Federal law eventually required reports of “preclinical tests (including tests on animals) before human trials could begin.”

This framework remained intact until 2022, when President Joe Biden signed the FDA Modernization Act 2.0. The Act removed the requirement that new drugs undergo animal testing before being tested in human clinical trials. Additionally, the law permitted developers to use alternatives, also called “new approach methodologies” (NAMs), such as cell-based assays, organ chips (small devices lined with human cells that mimic organs), computer simulations, and AI models to predict drugs’ toxicity. 

However, the FDA’s regulations did not change with the law. The FDA writes the regulations that drug developers follow, and changing these regulations––regardless of the statutes that Congress produces––must follow a lengthy procedure. Two years after the FDA Modernization Act 2.0 was signed into law, Senator Eric Schmitt (R-MO) noted that the FDA had not updated a number of rules that still called for animal testing. This mismatch created uncertainty for drug developers seeking to use newer methods. 

In February 2025, Congress introduced the FDA Modernization Act 3.0, which directed the FDA to replace references to animal tests with broader “nonclinal” language throughout its regulations. Senators Cory Booker (D-NJ), Eric Schmitt (R-MO), and Rand Paul (R-KY) led the Senate bill, while Representatives Buddy Carter (R-GA) and Nanette Barragán (D-CA) helped lead the House version. The Senate passed its bill by unanimous consent on December 16, 2025, and the House approved its bill by unanimous consent on July 20, 2026. Before the bill can reach President Donald Trump, the Senate must approve the House-passed version.

Political leaders on both sides have signaled support for the bill’s passage. Senate Majority Leader John Thune (R-SD) introduced the bill’s final Senate text on Booker’s behalf before it passed. Booker, typically a critic of the Trump administration, has praised the administration’s progress on this issue. Health and Human Services Secretary Robert F. Kennedy Jr. has also said that his department is “deeply committed to ending animal experimentation.” Agencies across the administration have followed suit: in January 2026, the Environmental Protection Agency committed to ending animal testing on mammals by 2035, while the National Institutes of Health has stopped awarding grants that rely solely on animal testing.

The FDA has also moved forward on its own. In April 2025, then-FDA Commissioner Marty Makary unveiled the agency’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The roadmap targets monoclonal antibodies (laboratory-made proteins that are used to treat diseases such as cancer), and is planned to be expanded to other drugs. 

In April 2026, the FDA reported that it had met its first-year goals surrounding the reduction of animal testing. This included launching a database of accepted NAMs, eliminating requirements for six-month studies in nonhuman primates for monoclonal antibodies, and qualifying its first AI drug development tool. The European Commission also adopted its own roadmap to phase out animal use in chemical safety assessments. 

Supporters argue that replacing animal testing will improve drug safety and lower research and development costs (ultimately allowing drugs to reach patients at lower price points). However, the Federation of American Societies for Experimental Biology (FASEB) cautioned that the FDA’s own supporting materials reflect a continued need for animal models across drug classes and disease areas. Additionally, many animal welfare advocates have criticized the roadmap, arguing that its scope is too narrow and that it relies on scientists adopting new methods without creating realistic enforcement standards. 

Overall, these debates reveal that the divide over animal testing falls not along party lines, but between those who want to move faster and those who want to move more carefully toward alternative methods of drug standards. Thus, whether scientific evidence supports this shift remains unknown. The FDA must sustain its previous progress amid a transfer of leadership from Marty Makary to Kyle Diamantas, the FDA’s acting commissioner. Further, AI-based safety models must prove successful in real drug approvals, rather than pilot programs. For the first time since 1938, the standards surrounding drug safety are open to revision, and the answer is likely to rest equally on both data and legislation.

Next
Next

Smart Health: How Artificial Intelligence Is Reshaping Public Health